FCGR3B
Low affinity immunoglobulin gamma Fc region receptor III-B
Also known as: CD16, CD16b, FCG3, FCG3B_HUMAN, FcgammaRIIIb, FCGR3, FcRIIIb
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- O75015
- Gene
- FCGR3B
- Ensembl
- ENSG00000162747
- Chromosome
- 1
- Canonical length
- 233 aa
- Protein class
- CD markers, FDA approved drug targets, Human disease related genes, Plasma proteins, Predicted intracellular proteins, Predicted membrane proteins, Predicted secreted proteins, Transporters
- Secretome location
- Secreted to blood
OverviewNCBI Gene
The protein encoded by this gene is a low affinity receptor for the Fc region of gamma immunoglobulins (IgG). The encoded protein acts as a monomer and can bind either monomeric or aggregated IgG. This gene may function to capture immune complexes in the peripheral circulation. Several transcript variants encoding different isoforms have been found for this gene. A highly-similar gene encoding a related protein is also found on chromosome 1. [provided by RefSeq, Aug 2012]
Canonical amino-acid sequenceUniProt
233 residues, UniProt reviewed canonical sequence.
>O75015|FCGR3B
1 MWQLLLPTAL LLLVSAGMRT EDLPKAVVFL EPQWYSVLEK DSVTLKCQGA YSPEDNSTQW
61 FHNENLISSQ ASSYFIDAAT VNDSGEYRCQ TNLSTLSDPV QLEVHIGWLL LQAPRWVFKE
121 EDPIHLRCHS WKNTALHKVT YLQNGKDRKY FHHNSDFHIP KATLKDSGSY FCRGLVGSKN
181 VSSETVNITI TQGLAVSTIS SFSPPGYQVS FCLVMVLLFA VDTGLYFSVK TNILocalizationUniProt · AlphaFold · HPA
Whether an antibody against FCGR3B can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Cell surface
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.37
- Highest tissue expression
- 78 nTPM
Expression across tissuesHPA
Tissue
- spleen: 78 nTPM
- appendix: 67 nTPM
- bone marrow: 31 nTPM
- lung: 22 nTPM
- tongue: 21 nTPM
- adipose tissue: 19 nTPM
Single-cell type
- neutrophils: 41 nCPM
- microglia: 1.9 nCPM
- neutrophil progenitors: 1.1 nCPM
- nk-cells: 0.5 nCPM
- proximal tubule cells: 0.2 nCPM
- renal collecting duct intercalated cells: 0.2 nCPM
Immune cell
- neutrophil: 6,078 nTPM
- non-classical monocyte: 17 nTPM
- eosinophil: 9.8 nTPM
- intermediate monocyte: 6.4 nTPM
- total PBMC: 5.6 nTPM
- gdT-cell: 2.3 nTPM
Brain region
- cerebral cortex: 11 nTPM
- pons: 4.2 nTPM
- thalamus: 1.1 nTPM
- basal ganglia: 0.9 nTPM
- choroid plexus: 0.9 nTPM
- medulla oblongata: 0.4 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about FCGR3B.
Disease | AutoantibodyPubMed
Conditions in which antibodies against FCGR3B are reported. Each links to that disease's full target list.
Showing 1 of 2 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for FCGR3B from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
20 publications
- Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process.
1994 · Clin Exp Immunol · RCR 5.8 · 208 citations - Anti-TNF-α therapy may cause neonatal neutropenia.
2014 · Pediatrics · RCR 1.8 · 41 citations - Neutrophil antibody specificity in different types of childhood autoimmune neutropenia.
1999 · Blood · RCR 1.7 · 61 citations - Genetic variations in low-to-medium-affinity Fcγ receptors and autoimmune neutropenia in early childhood in a Danish cohort.
2023 · Int J Immunogenet · RCR 1.1 · 7 citations - Targeting FcγRs to treat antibody-dependent autoimmunity.
2016 · Autoimmun Rev · RCR 1.1 · 32 citations
Show 15 more
- Natural killer and natural killer-like cell activity of peripheral blood and intrathyroidal mononuclear cells from patients with Graves' disease.
1988 · J Clin Endocrinol Metab · RCR 0.9 · 35 citations - The use of rhG-CSF in chronic autoimmune neutropenia: reversal of autoimmune phenomena, a case history.
1996 · Br J Haematol · RCR 0.9 · 28 citations - Peripheral blood lymphocyte imbalance in Koreans with active vitiligo.
1993 · Int J Dermatol · RCR 0.9 · 22 citations - Anti-CD16 autoantibodies and delayed phagocytosis of apoptotic cells in primary biliary cirrhosis.
2008 · J Autoimmun · RCR 0.7 · 30 citations - Cross-linking of human FcgammaRIIIb induces the production of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor by polymorphonuclear neutrophils.
2001 · J Immunol · RCR 0.5 · 21 citations - An Fc gamma RIII (CD16)-specific autoantibody from a patient with progressive systemic sclerosis.
1993 · Immunol Lett · RCR 0.4 · 19 citations - The presence of anti-Fc gamma receptor autoantibodies is related to the clinical presentation of primary Sjögren's syndrome.
1995 · J Rheumatol · RCR 0.3 · 10 citations - Differential effects of anti-Fc gamma RIIIb autoantibodies on polymorphonuclear neutrophil apoptosis and function.
2001 · J Leukoc Biol · RCR 0.3 · 12 citations - Development of proteoglycan-induced arthritis is critically dependent on Fcgamma receptor type III expression.
2005 · Arthritis Rheum · RCR 0.2 · 12 citations - Pathogenic effects of anti-Fc gamma receptor IIIb (CD16) on polymorphonuclear neutrophils in non-organ-specific autoimmune diseases.
2002 · Autoimmun Rev · RCR 0.2 · 10 citations - Soluble Fcgamma receptor IIIb alters the function of polymorphonuclear neutrophils but extends their survival.
2001 · Eur J Immunol · RCR 0.2 · 9 citations - [Neutropenia due to antibodies against Type III Fc receptors on neutrophil granulocytes: 3 children with different clinical courses].
1998 · Ned Tijdschr Geneeskd · RCR 0.1 · 2 citations - Decreased Fcgamma receptor III (CD16) expression on peripheral blood mononuclear cells in patients with Sjögren's syndrome.
1998 · J Rheumatol · RCR 0.1 · 3 citations - Ars2-containing bispecific, Fab- and IgG1-format BAR-bodies to target DLBCL cells.
2023 · EJHaem · RCR 0.1 · 1 citations - Consequences of Fc gamma receptor type III reactivity in non-organ-specific autoimmune diseases.
2002 · Biochem Soc Trans · RCR 0 · 1 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.65
- gnomAD pLI
- 0
- gnomAD missense Z
- -1.09
- DepMap mean gene effect
- 0.18
- DepMap dependency class
- none
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of FCGR3B in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads FCGR3B as an antibody target. Whether an autoantibody or antibody against FCGR3B could matter depends on whether native FCGR3B is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
FCGR3B is annotated at the cell surface, where native FCGR3B is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.
Annotation status
The present source text does not explicitly label FCGR3B as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...